(Q34273726)

1 August 2017

title

Lenalidomide after stem-cell transplantation for multiple myeloma (English)

1 reference

stem cell transplantation

1 August 2017

main subject

1 reference

1 reference

Sergio Giralt

1 reference

1 August 2017

Kenneth C Anderson

1 reference

1 August 2017

Paul G Richardson

1 reference

1 August 2017

Edward A Stadtmauer

1 reference

1 August 2017

David D Hurd

1 reference

1 August 2017

Koen Van Besien

1 reference

1 August 2017

Philip L McCarthy

1 reference

1 August 2017

Marcelo C Pasquini

1 reference

1 August 2017

Robert Schlossman

1 reference

1 August 2017

Ravi Vij

1 reference

1 August 2017

Heather Landau

1 reference

1 August 2017

Craig C Hofmeister

1 reference

1 August 2017

Hani Hassoun

1 reference

1 August 2017

Daniel J Weisdorf

1 reference

1 August 2017

Jan S Moreb

1 reference

1 August 2017

Teresa Gentile

1 reference

1 August 2017

Luis Isola

1 reference

1 August 2017

Richard T Maziarz

1 reference

1 August 2017

Asad Bashey

1 reference

1 August 2017

Muzaffar H Qazilbash

1 reference

1 August 2017

Brian McClune

1 reference

1 August 2017

Vera Hars

1 reference

1 August 2017

Cara Rosenbaum

1 reference

1 August 2017

Parameswaran Hari

1 reference

1 August 2017

Steven M Devine

1 reference

1 August 2017

Kouros Owzar

1 reference

1 August 2017

Natalie Scott Callander

1 reference

1 August 2017

Don A Gabriel

1 reference

1 August 2017

Thomas Martin

1 reference

1 August 2017

Denise Levitan

1 reference

1 August 2017

John Postiglione

1 reference

1 August 2017

Chen Jiang

1 reference

1 August 2017

Elizabeth Bennett

1 reference

1 August 2017

Susan Barry

1 reference

1 August 2017

Linda Bressler

1 reference

1 August 2017

Michael Kelly

1 reference

1 August 2017

Michele Seiler

1 reference

1 August 2017

Mary M Horowitz

1 reference

1 August 2017

Thomas C Shea

1 reference

1 August 2017

Charles Linker

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 May 2012

1 reference

The New England Journal of Medicine

1 August 2017

published in

1 reference

1 August 2017

volume

366

1 reference

1 August 2017

1 reference

1 August 2017

page(s)

1770-1781

1 reference

Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

Improved survival in multiple myeloma and the impact of novel therapies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

International uniform response criteria for multiple myeloma.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

Toxicity and response criteria of the Eastern Cooperative Oncology Group

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

How I treat multiple myeloma in younger patients

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

Multiple myeloma and acute myelomonocytic leukemia

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3744390

Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials

28 October 2018

1 reference

12 December 2020

Stem cell leukaemia in myelomatosis

1 reference

12 December 2020

Remission maintenance therapy for multiple myeloma

1 reference

12 December 2020

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

1 reference

12 December 2020

Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma

1 reference

12 December 2020

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

1 reference

12 December 2020

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

1 reference

12 December 2020

Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients

1 reference

12 December 2020

Identifiers

DOI

10.1056/NEJMOA1114083

1 reference

1 August 2017

1 reference

1 August 2017

1 reference